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Abstract
Background: Biallelic BRCA1 mutations are regarded either embryonically lethal 
or to cause Fanconi anemia (FA), a genomic instability syndrome characterized 
by bone marrow failure, developmental abnormalities, and cancer predisposition. 
We report biallelic BRCA1 mutations c.181T > G (p.Cys61Gly) and c.5096G > A 
(p.Arg1699Gln) in a woman with breast cancer diagnosed at the age of 30 years. The 
common European founder mutation p.Cys61Gly confers high cancer risk, whereas 
the deleterious p.Arg1699Gln is hypomorphic and was suggested to confer interme-
diate cancer risk.
Methods and Results: Aside from significant toxicity from chemotherapy, the 
patient showed mild FA‐like features (e.g., short stature, microcephaly, skin hy-
perpigmentation). Chromosome fragility, a hallmark of FA patient cells, was not 
present in patient‐derived peripheral blood lymphocytes. We demonstrated that the 
p.Arg1699Gln mutation impairs DNA double‐strand break repair, elevates RAD51 
foci levels at baseline, and compromises BRCA1 protein function in protecting from 
replication stress. Although the p.Arg1699Gln mutation compromises BRCA1 func-
tion, the residual activity of the p.Arg1699Gln allele likely prevents from chromo-
some fragility and a more severe FA phenotype.
Conclusion: Our data expand the clinical spectrum associated with biallelic BRCA1 
mutations, ranging from embryonic lethality to a mild FA‐like phenotype and no 
chromosome fragility.
K E Y W O R D S
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1 |  INTRODUCTION
Monoallelic germline mutations in the BRCA1 and BRCA2 
confer high life‐time risks for breast cancer (BC) and ovarian 
cancer (OC) (Kuchenbaecker et al., 2017) and were found in 
approximately 24% of index patients who met the inclusion 
criteria of the German Consortium for Hereditary Breast and 
Ovarian Cancer (GC‐HBOC) for germline testing (Kast et al., 
2016). BRCA1/BRCA2‐related BC and OC susceptibility is 
inherited in an autosomal dominant manner with incomplete 
penetrance (Kuchenbaecker et al., 2017).
Biallelic (i.e., homozygous/compound heterozygous) 
mutations in the BRCA2 cause Fanconi anemia (FANCD1, 
MIM# 605724), a recessive, congenital genomic instability 
syndrome generally characterized by bone marrow failure, 
developmental abnormalities in various organ systems and a 
high predisposition for hematological or solid tumors. Despite 
a similar mutation prevalence of the BRCA2 and BRCA1 in 
the general population (Maxwell, Domchek, Nathanson, & 
Robson, 2016), biallelic mutations affecting the BRCA1 are 
rarely described and have been suggested as lethal during em-
bryonic development (Goldgar et al., 2004), consistent with 
the embryonic lethality observed in Brca1 null mice (Evers & 
Jonkers, 2006). In 2013, however, Domchek et al. described 
a 28‐year‐old woman with OC and an otherwise complex 
phenotype suggesting Fanconi anemia (FA). Medical re-
cords revealed short stature, microcephaly, developmental 
delay, and significant toxicity from chemotherapy. The pa-
tient carried a protein‐truncating variant (p.Asp821Ilefs*25) 
and a pathogenic missense variant (p.Val1736Ala) in trans 
(Domchek et al., 2013). In 2015, Sawyer et al. reported bi-
allelic BRCA1 mutations (p.Ser198Argfs*35 and p.Arg-
1699Trp) in a woman with multiple congenital anomalies 
consistent with a FA‐like disorder (phenotype subsequently 
referred to as FANCS, MIM# 617883) and BC at the age of 
23 years (Sawyer et al., 2015). Freire et al. described a 2.5‐
year‐old girl of consanguineous offspring with severe short 
stature, microcephaly, neurodevelopmental delay, congenital 
heart disease and dysmorphic features, and the girl was a ho-
mozygous carrier of a BRCA1 nonsense mutation in exon 11 
(p.Cys903*) (Freire et al., 2018). In 2018, Seo et al. reported 
multiple congenital anomalies and severe chromosomal fra-
gility in children of consanguineous offspring, all homozy-
gously carrying BRCA1 nonsense mutations affecting exon 
11 (p.Trp372*, p.Leu431*)(Seo et al., 2018). Of note, mi-
tomycin C‐ or diepoxybutane (DEB)‐induced chromosome 
fragility assays performed by Seo et al. are routinely used to 
confirm clinical FA diagnosis (Castella et al., 2011).
In this study, we report a female index patient with two 
deleterious BRCA1 missense alterations in a compound 
F I G U R E  1  Pedigree and germline mutation status. (a) Cancer family history of the index patient (III‐1, marked with an arrow), including age 
at first diagnosis. BC = breast cancer; PC = prostate cancer; y = years. The index patient's mother (II‐2) had no personal history of cancer at the 
age of 60 years. The maternal grandfather of the index patient was diagnosed with prostate cancer at the age of 80 years. The index patient's father 
(II‐1) had no personal history of cancer at the age of 59 years. The paternal grandmother of the index patient was diagnosed with breast cancer at 
the age of 42 years and died at the age of 87 years. No other cancer cases were reported in the family. (b) Sanger sequencing electropherograms 
show BRCA1 genotypes (BRCA1 reference transcript NM_007294.3) of the index patient III‐1 and both parents (II‐1, II‐2). Red arrows mark the 
presence of a single nucleotide substitution
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F I G U R E  2  (a) Analysis of DSB‐induced HR activities in individuals with wild‐type, mono‐ or biallelic mutations in the BRCA1. To 
measure the repair of DSBs by HR, we used the EGFP‐based reporter substrate HR‐EGFP/5'EGFP consisting of mutated EGFP genes with an 
I‐SceI endonuclease recognition sequence replacing 4 bp (HR‐EGFP) and a 3' truncation (5'EGFP), respectively. The DSB repair substrate for the 
determination of HR frequencies is schematically drawn on top (Akyuz et al., 2002). I‐SceI recognition sequence, red triangle; cross, truncating 
mutation; white bars, mutated EGFP genes; dark green bars, reconstituted EGFP; blue bar, spacer sequence; gray bar with kinked arrow, 
transcriptional promoter; scissors, I‐SceI endonuclease. HR measurements were performed 24 hr following transfection of PBLs (left diagram) or 
LCLs (right diagram) from individuals with BRCA1 (p.Arg1699Gln) or BRCA1 (p.Cys61Gly/p.Arg1699Gln) with HR‐EGFP/5´EGFP substrate 
plus I‐SceI expression plasmid for substrate cleavage. Measurements for PBLs with wild‐type BRCA1 were obtained from one (left diagram) 
and two (right diagram) independent control individuals. Percentages of EGFP‐positive live cells were normalized to the individually determined 
transfection efficiencies for HR frequency calculations. Mean values of wild‐type controls were set to 100% (absolute mean frequency: 0.2%). 
Mean values and standard errors of the mean (SEM) from 3 to 5 measurements are shown. (b) Immunofluorescence microscopic analysis of DNA 
damage and RAD51 nucleofilament formation. Nuclear foci of the DNA damage marker γH2AX (left diagram) and of RAD51 (right diagram), 
indicating nucleofilament formation, were analyzed in PBLs from individuals with wild‐type and mutated BRCA1 (p.Arg1699Gln, p.Cys61Gly/p.
Arg1699Gln) 1 and 6 hr after treatment with 2 Gy ionizing radiation (IR) and in untreated samples. Immunolabeled foci were scored by automated 
quantification from 97 to 115 nuclei per sample. Mean foci/cell and SEM are graphically shown on the left side. Statistically significant differences 
were determined using nonparametric Mann–Whitney test for unpaired samples with the software GraphPad Prism version 7.03. *p < .05; 
**p < .01; ***p < .001; ****p < .0001. Representative images of green γH2AX and red RAD51 foci in DAPI‐stained nuclei (blue) 6 hr post‐IR 
are shown on the right side. The size bar indicates 5 µm. (c) Analysis of replication fork protection following stalling. Single DNA fiber analysis 
was performed as schematically outlined in the sketch on top. Representative fibers ∓ HU are shown for the patient carrying biallelic BRCA1 
mutations (p.Cys61Gly/p.Arg1699Gln). The size bar indicates 5 µm. CldU track length distributions of CldU‐ and IdU‐positive DNA fibers from 
PBLs derived from individuals with wild‐type and mutated BRCA1 (p.Arg1699Gln, p.Cys61Gly/p.Arg1699Gln) were determined in the presence 
of HU, indicating replication stalling (right) or absence of HU for unperturbed replication. Mean values were calculated from fiber track lengths 
of 106–172 single fibers in each sample. Statistically significant differences between PBLs from individuals with wild‐type and mutated BRCA1 
(p.Cys61Gly/p.Arg1699Gln) were calculated using Dunn's test. ***p < .001; ****p < .0001
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heterozygous state, namely, c.181T  >  G (p.Cys61Gly) and 
c.5096G > A (p.Arg1699Gln) (Bouwman et al., 2013; Lindor 
et al., 2012). The c.181T > G (p.Cys61Gly) alteration is one 
of the most common pathogenic BRCA1 founder mutations 
in Europe (Rebbeck et al., 2018) and a well‐established high‐
risk variant (Lindor et al., 2012), whereas the deleterious 
p.Arg1699Gln mutation is hypomorphic and was suggested 
to confer intermediate cancer risk (Bouwman et al., 2013; 
Moghadasi et al., 2018; Spurdle et al., 2012).
2 |  MATERIALS AND METHODS
2.1 | Testing for germline mutations in 
cancer predisposition genes
The index patient III‐1 and her parents (Figure 1a) were coun-
seled at the Center for Hereditary Breast and Ovarian Cancer, 
University Hospital of Cologne, Germany. Physicians quali-
fied in genetic counseling recorded personal and family can-
cer history, information regarding age at first diagnosis, tumor 
receptor status, and treatment of the index patient. Written in-
formed consent was obtained from all individuals, and ethical 
approval was granted by the ethics committee of the University 
of Cologne (07‐048). Genomic DNA was isolated from venous 
blood samples. Next generation sequencing technology was 
applied using an Illumina MiSeq sequencing device (Illumina, 
San Diego, USA) and the customized diagnostic TruRisk® 
multigene panel for target enrichment (Agilent, Santa Clara, 
USA) covering BRCA1, BRCA2, and additional breast/ovarian 
cancer predisposition genes (ATM, BRIP1, CDH1, CHEK2, 
PALB2, RAD51C, RAD51D, TP53). Variant classification was 
performed in accordance with the regulations of the interna-
tional ENIGMA consortium (Evidence‐based Network for the 
Interpretation of Germline Mutant Alleles; https ://enigm acons 
ortium.org; version 1.1:26 March 2015).
2.2 | Blood‐derived cell cultures for 
functional analyses
The DEB‐induced chromosome fragility assay was per-
formed as described previously (Castella et al., 2011). 
PBLs were partially isolated from heparinized blood sam-
ples by Ficoll‐Paque‐PLUS, (LSM 1077 Lymphocyte, GE 
Healthcare, Germany) gradient centrifugation followed by 
several washing steps with PBS to remove thrombocytes, 
and the samples were then gently frozen as described 
(Deniz, 2017). The remaining fractions of the blood sam-
ples from the index patient (III‐1, Figure 1a) and her 
mother (II‐2, Figure 1a) were subjected to the establish-
ment of LCLs by EBV‐immortalization of peripheral blood 
mononuclear cells. Aliquots from two reference blood 
samples were obtained from healthy female donors aged 28 
and 26 (approval #157/2010 and amendment 2016 by the 
ethics committee of Ulm University), from which aliquots 
of the same blood draw had previously served as references 
in a recent case–control study (Deniz, 2017). LCLs from 
three reference individuals age 49–56 were used as con-
trols during measurements of microhomology‐mediated 
end joining (Figure S1a). Thawed PBLs were cultivated 
in PB‐MAXTM Karyotyping Medium (Gibco/Invitrogen, 
Carlsbad, CA, USA) including 2% phytohemagglutinin 
(PAA, Pasching, Germany) for 72  hr. LCLs were culti-
vated as previously described (Gatz et al., 2016) and used 
for HR measurements at passage 2–6.
2.3 | EGFP‐based reporter for DSB repair 
measurements
To analyze DSB repair via HR or microhomology‐mediated 
end joining, we used our enhanced green fluorescent protein 
(EGFP)‐based test system, as described earlier (Akyuz et al., 
2002; Deniz, 2017; Obermeier et al., 2016). Briefly, the ex-
pression plasmid for the endonuclease I‐SceI (pCMV‐I‐SceI) 
together with HR or microhomology‐mediated end joining 
substrate (Figure 2a and Supp. Figure S1a) and filler plas-
mid (pBlueScriptII KS; Stratagene, Heidelberg, Germany) 
or wild‐type EGFP reporter plasmid (for determination of 
transfection efficiencies) were transfected into PBLs or 
LCLs using amaxa reagents (Lonza, Cologne, Germany). 
After 24 hr of cultivation, reconstitution of wild‐type EGFP 
was determined by FACS analysis of the fraction of green 
fluorescent cells among living cells identified by gating in 
the FL1/FL2 and side scatter/forward scatter dot plots fol-
lowing laser excitation at 488 nm (FACS Calibur FACScan, 
Becton Dickinson, Heidelberg, Germany). Each quantifica-
tion of green fluorescent cells monitoring DSB repair was 
normalized using the individually determined transfection 
efficiency (20%–60%) to calculate the DSB repair frequency.
2.4 | Nuclear foci analysis by 
immunofluorescence microscopy
For in situ analysis of DSB repair by HR, we performed im-
munofluorescence microscopic analysis of the DNA damage 
marker γH2AX and the recombinase RAD51 in PBLs after 
exposure to 2 Gy of ionizing radiation (IR) as previously de-
scribed (Gatz et al., 2016; Obermeier et al., 2016). Briefly, 
PBLs were harvested by cytospinning at the indicated time 
points postirradiation, fixed with 3.7% formaldehyde fol-
lowed by permeabilization with 0.5% TritionX‐100. Primary 
antibodies were directed against γH2AX (Ser139, clone 
JBW301, Millipore, Billerica, MA, USA) and RAD51 (H‐92, 
Santa Cruz Biotechnology, Heidelberg, Germany), and the 
secondary antibodies were AlexaFluor488 and 555‐labeled 
(Invitrogen, Karlsruhe, Germany). Immunostained cells 
were mounted with VectaShield mounting media containing 
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DAPI (Vector laboratories, Burlingame, CA, USA). Focal 
accumulations of 53BP1 and RAD51 in ≥97 DAPI‐stained 
nuclei from two independent slides were analyzed using a 
Keyence BZ‐9000 microscope equipped with Keyence BZ‐II 
Analyzer software (Keyence, Neu‐Isenburg, Germany).
2.5 | Cellular sensitivity to PARP 
inhibition and carboplatin
To assess the response to the PARP inhibitor olaparib 
(Biozol, Eching, Germany), PBLs were treated with vari-
ous olaparib concentrations (0.5–512 μmol/L) or carboplatin 
(0.125–2048 µmol/L) for 24 hr and subsequently re‐cultivated 
in fresh medium for 24 hr. Cell viabilities after the different 
treatments were determined in duplicate using the 3‐(4,5‐di-
methylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) 
assay as described (Deniz, 2017).
2.6 | DNA fiber assay for nascent 
DNA synthesis
Cells were labeled with 20  µmol/L 5‐chloro‐2‐deoxyu-
ridine (CldU, Sigma‐Aldrich, Steinheim, Germany) for 
30 min and centrifuged for 2 min to discard CldU‐contain-
ing medium before treating the cells with 5  mmol/L hy-
droxyurea (HU, Sigma‐Aldrich, Steinheim, Germany) for 
30  min or mock‐treated. To discard HU‐containing me-
dium, the cells were centrifuged for 2 min, then, the cells 
were incubated with 200  µmol/L 5‐Iodo‐2 deoxyuridine 
(IdU, Sigma‐Aldrich, Steinheim, Germany) for 30 min. For 
cell harvesting, the cells were centrifuged for 2  min and 
washed once with 1 × DPBS before the cell pellet was re‐
suspended in 1 × DPBS. Cell‐spotting, cell lysis, fixation 
and immunofluorescence staining were performed as pre-
viously described (Hampp et al., 2016). Briefly, the cells 
were spotted on a slide, and the DNA spreading was per-
formed via gravity before fixation in methanol/acetic acid. 
For denaturation/depurination, glass slides were incubated 
in HCl before immunofluorescence staining.
2.7 | Statistical analyses
Statistically significant differences between mean values 
of DSB repair frequencies or nuclear foci/cell numbers 
were calculated using the Mann–Whitney test for unpaired 
samples with the software GraphPad Prism version 7.03. 
GraphPadPrism 7.03 was also used for calculating IC50 val-
ues and to test for significant differences between olapa-
rib‐response curves using the extra sum‐of‐squares F‐test. 
Kruskal–Wallis based Dunn's multiple comparison test was 
used for the calculation of statistically significant differences 
in nascent DNA synthesis. All p‐values are two‐sided with 
p < .05 considered statistically significant.
3 |  RESULTS
3.1 | Clinical findings
The female index patient presented at the age of 30  years 
with an invasive‐ductal carcinoma of her left breast (G3; 
Ki67 30%). The 35‐mm tumor expressed estrogen receptors 
but tested negative for progesterone receptor and epidermal 
growth factor receptor 2 expression/overexpression. At the 
time of the BC diagnosis, the patient's blood count was incon-
spicuous. During her childhood, she obtained diagnoses of 
hearing loss (right side), celiac disease and congenital hip dis-
location (left side) and had a hip operation at 11 years. A dys-
morphology exam revealed a short height (150 cm, <5%ile 
for adult height) (de Onis et al., 2007), microcephaly (52 cm, 
<5%ile for adult head circumference), triangular face with 
low placed ears, and skin hyperpigmentation (several café au 
lait macules). No further FA‐like features were observed (no 
limb defects; no ophthalmic, endocrine, genitourinary tract, 
spine or neck anomalies; no congenital heart defect; no gas-
trointestinal malformations; no central nervous system anom-
alities). Her parent's heights were unconspicuous (mother: 
179  cm, father: 185  cm). Following BC diagnosis, she re-
ceived neoadjuvant chemotherapy starting with four cycles 
epirubicin/cyclophosphamide (90/600 mg/m2 body surface). 
Doses were reduced during the fourth cycle due to hemato-
toxicity (75/400 mg/m2 body surface). She subsequently was 
treated with paclitaxel (80 mg/m2 body surface), which was 
combined with carboplatin (AUC 5) starting from the sec-
ond cycle. Due to recurring thrombopenia, neutropenia, and 
anemia, she received reduced doses of paclitaxel (70 mg/m2 
body surface) and carboplatin (AUC 1.5). As a result of the 
prolonged thrombopenia, neutropenia, and anemia, chemo-
therapy was discontinued after four cycles, followed by mas-
tectomy, and radiotherapy and antihormone therapy.
3.2 | Cancer family history and germline 
mutation status
The pedigree of the index patient III‐1 is shown in Figure 
1a. The index patient met the inclusion criteria of the 
German Consortium for Hereditary Breast and Ovarian 
Cancer (GC‐HBOC) for germline testing, which was per-
formed by next generation sequencing (NGS) using the 
TruRisk® gene panel. Two heterozygous missense mu-
tations, c.5096G  >  A (p.Arg1699Gln) and c.181T  >  G 
(p.Cys61Gly), in the BRCA1 were detected, which both 
were confirmed by Sanger sequencing (Figure 1b). Genetic 
testing of the patient's parents via Sanger sequencing re-
vealed that the c.5096G  >  A (p.Arg1699Gln) mutation 
was inherited from the patient's mother (II‐2), whereas the 
c.181T > G (p.Cys61Gly) mutation was inherited from the 
patient's father (II‐1).
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3.3 | Diepoxybutane (DEB)‐induced 
chromosome fragility assay
Chromosome fragility is usually reported as “percentage of 
aberrant cells” and “breaks/cell.” The number of “breaks/
cell” is more than 10 times higher in the FA population than 
in the non‐FA population, while the “percentage of aber-
rant cells” is increased 60 times in FA patients (Castella et 
al., 2011). To determine whether a FA phenotype may be 
present on the cellular level using peripheral blood lym-
phocytes (PBLs) derived from the index patient (III‐1) and 
her unaffected mother (II‐2), we used an established DEB‐
induced chromosome fragility assay described previously 
(Castella et al., 2011). Both the index patient (6% of cells 
with breaks, 0.12 breaks/cell) and her unaffected mother 
(10% of cells with breaks, 0.17 breaks/cell) showed DEB‐
induced chromosome fragility within the control range (4% 
of cells with breaks, range 0%–22%; 0.05 breaks/cell, range 
0–0.5). These inconspicuous results prompted us to inves-
tigate the hypomorphic p.Arg1699Gln allele, which was 
suggested to confer intermediate cancer risk (Bouwman et 
al., 2013; Moghadasi et al., 2018; Spurdle et al., 2012), 
in more detail. The BRCA1 BRCT domain p.Arg1699Gln 
mutation in the index patient III‐1 and her mother II‐2 
(Figure 1a) was described to weaken BACH1 phospho‐
peptide interactions (Clapperton et al., 2004), which are 
required for efficient error‐free homologous recombination 
(HR) repair (Xie et al., 2010).
3.4 | EGFP‐based reporter for DSB repair 
measurements
Given the close association between HR deficiency and the 
pathogenicity of BRCA1 mutations (Bouwman et al., 2013), 
we applied an EGFP‐based DNA double‐strand break (DSB) 
repair assay on fresh PBLs derived from the index patient, 
her unaffected mother and two female healthy donors func-
tionally representing wild‐type controls (Deniz, 2017; Gatz 
et al., 2016; Keimling et al., 2012) (Figure 2a). HR analysis 
indicated threefold reduced HR frequencies in PBLs from 
the patient as well as from the mother compared to the wild‐
type reference, although not reaching statistical significance 
(p = .1000), most likely due to the limited number of meas-
urements. This observation was supported in a second experi-
ment using early passage lymphoblastoid cell lines (LCLs) 
derived from the same blood draws of the patient and her 
mother. Compared to the mean values for wild‐type BRCA1 
status (obtained with two wild‐type PBL controls), a statisti-
cally significant twofold decrease in HR was scored for the 
LCLs from the mother carrying the BRCA1 p.Arg1699Gln 
mutation and sixfold for the LCLs from the index patient 
carrying both mutations, p.Cys61Gly and p.Arg1699Gln 
(p  =  .0357). Concomitantly, both LCLs showed four‐ to 
fivefold elevated microhomology‐mediated end joining com-
pared with three wild‐type LCLs (p =  .0182–.0091; Figure 
S1). These results indicated a defect in the HR machinery 
of the mother and the index patient, in particular, causing a 
derepression of error‐prone DSB repair. Notably, error‐prone 
DSB repair, such as microhomology‐mediated end joining, 
associates with BC/OC risk as previously shown for cells 
from BRCA1, BRCA2, and PALB2 mutation carriers as well 
as in a case–control format independently of the individual 
risk genotype (Keimling et al., 2012, 2011; Obermeier et al., 
2016).
3.5 | Nuclear foci analyses (γH2AX and 
RAD51) by immunofluorescence microscopy
To elucidate the molecular defect observed, we performed 
immunofluorescence microscopic analysis of focal nuclear 
structures indicative of the accumulation and/or removal of 
DSBs using antibodies against γH2AX and of the assem-
bly of the HR machinery using antibodies against RAD51. 
Prior to treatment, we observed 1.4‐fold elevated basal 
γH2AX foci levels in patient PBLs compared to PBLs from 
the mother and 1.8‐fold compared to the wild‐type control 
(Figure 2b). Moreover, basal RAD51 foci numbers were 
threefold higher in PBLs from the patient and mother than 
those in the control (Figure 2b). Because γH2AX foci were 
reported to mark not only DSBs but also other DNA lesions 
(Gagou, Zuazua‐Villar, & Meuth, 2010), and in particular, 
stalled replication forks triggering recombinative lesion by-
pass, our observation was consistent with pronounced repli-
cation stress marked by both γH2AX and RAD51 in patient 
cells. One hour after DSB induction by treatment of PBLs 
with 2 Gy ionizing radiation, γH2AX foci accumulated two‐ 
to threefold in all cell types (p < .001), thereby maintaining 
a relative twofold increment of γH2AX foci in patient cells 
(Figure 2b). At the same time point, RAD51 foci numbers 
still showed a similar pattern as before irradiation, because 
canonical nonhomologous end joining dominates during 
this early period of DSB repair (Deniz, 2017) (Figure 2b). 
However, 6 hr after irradiation, RAD51 foci were 3.4‐fold 
and 1.9‐fold elevated in cells from the control and mother, 
respectively (p < .001), when compared with 1 hr postirra-
diation (Figure 2b). No increase was observed in the patient 
cells suggesting a problem in RAD51 filament assembly 
during the late phase of DSB repair involving end process-
ing‐mediated pathways such as HR (Deniz, 2017). Since 
γH2AX‐labeled DSB scores were similar in the different 
PBL cultures at this late time point (Figure 2b), DSB repair 
in patient cells may have shifted towards mutagenic path-
ways. Microhomology‐mediated end joining was reported 
to become unleashed in HR defective cells (Keimling et al., 
2011) as demonstrated for the patient cells investigated here 
(Supp. Figure S1). Altogether, these data suggested that the 
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acquisition of the BRCA1 variant causing the p.Cys61Gly 
mutation on top of p.Arg1699Gln exchange severely al-
tered HR in the patient, resulting in accumulation of basal 
DNA damage and failure to assemble functional RAD51 
nucleofilaments.
3.6 | Cellular sensitivity to Poly(ADP‐
ribose) polymerase (PARP) inhibition and 
carboplatin
PARP inhibition causes synthetic lethality in combina-
tion with severe HR deficiency such as of tumor cells from 
BRCA1 or BRCA2 mutation carriers upon inactivation of 
the wild‐type allele (Bryant et al., 2005). Having identified 
increasing defectiveness in HR in the biallelically versus 
monoallelically BRCA1 mutated and wild‐type cells, we 
examined cell survival after exposure to increasing concen-
trations of the PARP inhibitor olaparib. Patient cells were 
highly sensitive to olaparib treatment as compared to the con-
trol and to cells from the mother, for which we determined 
an IC50 value showing only a trend towards a significant 
decrease compared with the control (p  <  .1) (Supp. Table 
S1). Conversely, after treatment with the DNA cross‐link-
ing agent carboplatin, we found no statistically significant 
difference between the IC50 values for the cells from the pa-
tient, mother or control (Table S1); although in parallel, we 
measured sensitivity changes in PBLs from a cohort of high 
BC/OC risk individuals (Deniz, 2017). These discrepant re-
sults could be because of DNA interstrand cross‐links, as 
discovered recently (Semlow, Zhang, Budzowska, Drohat, 
& Walter, 2016), and can be repaired by both HR‐dependent 
and ‐independent pathways.
3.7 | DNA fiber assay for nascent 
DNA synthesis
Schlacher, Wu, & Jasin (2012) demonstrated that BRCA2 
exerts functions in stabilizing DNA replication forks that can 
be separated from its role in promoting HR. Livingston and 
co‐workers (Pathania et al., 2014) observed that BRCA1 is 
haploinsufficient for the suppression of replication stress but 
not for RAD51 foci formation or PARP inhibitor sensitivity. 
To investigate the response of patient cells in the presence 
of replication stress, we analyzed the fate of nascent DNA 
replication tracks after treatment with hydroxyurea (HU), 
which causes the depletion of the deoxyribonucleotide pool 
(Figure 2c). In the absence of HU, replication track lengths 
were similar for PBLs from the mother or patient compared 
with the control (Figure 2c). However, tracks of PBLs from 
the mother and the patient were 30% and 40%, respectively, 
shorter after HU treatment compared to the control after HU 
treatment. Taken together, cells from both the mother carry-
ing the p.Arg1699Gln mutation and the patient with both the 
p.Cys61Gly and the p.Arg1699Gln mutations are compro-
mised in protecting nascent DNA from nucleolytic degrada-
tion during replication stress, whereas defective RAD51 foci 
formation postirradiation and olaparib hypersensitivity was 
observed with patient cells only.
4 |  DISCUSSION
We show the co‐occurrence of two deleterious BRCA1 al-
terations (p.Cys61Gly, p.Arg1699Gln) in trans with no cy-
togenetic features of FA observed, indicating that at least one 
mutation is hypomorphic. The inconspicuous cytogenetic and 
comparatively mild FA‐like clinical phenotype presented here 
is most likely due to incomplete impairment of BRCA1 func-
tion by the p.Arg1699Gln risk allele, which was described to 
intermediately increase BC/OC risks by the age of 70 years 
to 20% and 6%, respectively (Moghadasi et al., 2018; Spurdle 
et al., 2012). These calculated risks were considerably lower 
than those described for pathogenic mutations overall, which 
were associated with BC/OC risks by the age of 70 years of 
approximately 60% and 40%, respectively (Kuchenbaecker 
et al., 2017). Using PBLs/LCLs derived from the patient's 
unaffected mother, we demonstrated that the p.Arg1699Gln 
mutation impairs DSB repair causing a derepression of error‐
prone DSB repair (Figure 2a and Figure S1), elevates RAD51 
foci levels at baseline (Figure 2b), and compromises BRCA1 
protein function in protecting from replication stress (Figure 
2c). Although the p.Arg1699Gln mutation impairs DNA dou-
ble‐strand break repair and compromises BRCA1 function in 
protection from replication stress, the residual function of 
the p.Arg1699Gln allele likely prevents from chromosome 
fragility and a more severe FA phenotype. In addition, we 
cannot exclude a residual function of the BRCA1 protein car-
rying the p.Cys61Gly mutation.
In concert with published findings (Domchek et al., 2013; 
Freire et al., 2018; Sawyer et al., 2015; Seo et al., 2018), 
our data suggest that the phenotypic variability of biallelic 
BRCA1 mutations ranges from embryonic lethality to short 
body height, microcephaly, early onset BC and toxicity from 
chemotherapy, whereas residual BRCA1 protein function de-
termines the disease severity. For FA patients homozygously 
carrying nonsense mutations in exon 11 of the BRCA1 (Freire 
et al., 2018; Seo et al., 2018), it has been demonstrated that 
a naturally occurring alternative splicing isoform can enable 
survival, albeit with severe consequences (Seo et al., 2018). 
The index patient described by Sawyer et al. carried a pro-
tein‐truncating BRCA1 mutation, p.Ser198Argfs*35, along 
with the p.Arg1699Trp high‐risk variant which was shown 
to elevate the BC risk to 58% by the age of 70 years (Spurdle 
et al., 2012). Analyses of patient‐derived cells revealed de-
fective RAD51 foci formation and olaparib hypersensitivity, 
similar to the patient characterized in our study. In contrast, 
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however, the FANCS patient described by Sawyer et al. 
showed DEB‐caused cross‐linker–induced chromosomal ab-
errations, a hallmark of FA patient cells, which was not pres-
ent in our patient.
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